EPZM - Epizyme's Tazemetostat Is Approved And Other News: The Good Bad And Ugly Of Biopharma
Epizyme Wins FDA Approval for Rare Cancer Treatment Tazverik
Epizyme (EPZM) received accelerated approval from the Food and Drug Administration for Tazverik (Tazemetostat) treatment for patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma, a rare, slow-growing type of cancer. However, the company is carrying out a confirmatory trial, and the results of the trial will determine the continued approval of the drug. This trial is a global, randomized, and controlled confirmatory trial for evaluating the performance of combination of Tazverik plus doxorubicin in comparison to doxorubicin plus placebo as a